Abstract: Compositions and methods for modifying the production levels of alkaloids in plants are provided. Alkaloid production can be genetically controlled by modulating the transcriptional activation of PMT genes mediated by members of the ERF family and/or Myc family of transcription factors. Novel nucleotide sequences encoding the Myc family of transciption factors are also provided.

Abstract: A method of manufacturing a biopolymer optical device includes providing a polymer, providing a substrate, casting the polymer on the substrate, and enzymatically polymerizing an organic compound to generate a conducting polymer between the provided polymer and the substrate. The polymer may be a biopolymer such as silk and may be modified using organic compounds such as tyrosines to provide a molecular-level interface between the provided bulk biopolymer of the biopolymer optical device and a substrate or other conducting layer via a tyrosine-enzyme polymerization. The enzymatically polymerizing may include catalyzing the organic compound with peroxidase enzyme reactions. The result is a carbon-carbon conjugated backbone that provides polymeric “wires” for use in polymer and biopolymer optical devices. An all organic biopolymer electroactive material is thereby provided that provides optical functions and features.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Methods and systems are provided herein for on-line preparation of a sample for mass spectrometry. In accordance with various aspects of applicant's teachings, the methods and systems can provide for the reduction of a polypeptide, for example, on a liquid chromatography column and can reduce or eliminate the need to incubate the reducing agent with the polypeptide and/or expose the reduced polypeptide to an alkylating agent.

Abstract: The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

Abstract: The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.

Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.

Abstract: The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a VH or VL domain.

Abstract: The present invention provides a composite comprising a novel antibody and at least one selected from the group consisting of a solid phase support and a labeled substance. The antibody consists of the amino acid sequence represented by SEQ ID NO: 08, and is capable of binding to an intranuclear protein of an influenza virus type A. The influenza virus type A is at least one selected from the group consisting of H1N1, H2N2, H3N2, and H7N9. The antibody is bound to the at least one selected from the group consisting of the solid phase support and the labeled substance. The present invention also provides a detection device and a detection method using the composite.

Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.

Abstract: Herein are reported glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule?linkern)m?conjugation partner?(linkero?repeat-motif-molecule)p, wherein n and o are independently of each other and independently for each value of m and p integer values of 0 or 1, and m and p are independently of each other integer values of 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7, and wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site. Also reported are encoding nucleic acids and method for producing these repeat-motif-conjugates in mammalian cells.

Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.

Abstract: The present invention provides an antitumor agent having high safety, which is a molecular target drug against malignant tumors. An anti-malignant tumor agent characterized by containing, as an active ingredient, a substance targeting ribosomal proteins shows increased expression in malignant tumor cells. The substance of the present inventions targeting the ribosomal protein showing increased expression in the malignant tumor cell may be a substance involved in one of biological defense mechanisms which are considered to be intrinsically provided in a living body and prevent onset of disease even if cancer cells develop. Specifically, the ribosomal protein showing increased expression is RPL29 and/or RPS4X.

Abstract: The invention relates to a method of increasing protein biomolecule production in which a) a cell that produces a heterologous protein biomolecule is cultured, and b) an Additive and/or a source of the Additive is added to the culture medium in an amount sufficient to (i) increase a total yield of the heterologous protein biomolecule secreted into the cell culture media and/or (ii) increase a specific cellular productivity of the heterologous protein biomolecule secreted into the cell culture media.

Abstract: The present invention relates to antibody which binds to an epitope located within the BMPR1 binding region of BMP4.

Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.

Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.

Abstract: Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.

Abstract: The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.

Abstract: Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.

Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.

Abstract: The present invention relates to linkers, containing amide surrogates with a regular or a novel lysosomal enzymatic cleavable dipeptidic unit, to connect cytotoxic drugs to antibodies. The present invention also relates to ADCs (antibody-drug conjugates) derived from these amide surrogate linkers for the treatment of cancers.

Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.

Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

Abstract: A modified conjugated diene-based polymer is produced by reacting a conjugated diene-based polymer having an alkali metal or an alkali-earth metal at a terminal of the polymer with a compound represented by formula (1). R1 and R2 independently represent a hydrocarbyl group having 20 or fewer carbon atoms. R3 represents a substituted alkyl group having 20 or fewer carbon atoms prepared through substitution of at least one of a hydrogen atom and —CH2— of an alkyl group by a group containing only at least one heteroatom selected from the group consisting of nitrogen, phosphorus, oxygen, and sulfur, or a monovalent aromatic group having 20 or fewer carbon atoms and containing at least one element selected from the group consisting of nitrogen, phosphorus, oxygen, and sulfur, with the proviso that R3 does not have active hydrogen. R4 represents an alkanediyl group having 20 or fewer carbon atoms. n is 1 or 2.

Abstract: Olefin polymerization catalyst systems and methods for making and using the same are provided.

Abstract: This invention relates to novel transition metal catalyst compounds comprising four oxygen atoms bonded to a transition metal where two of the oxygen groups are bonded to the metal by dative bonds and a silyl or germyl bridge, catalyst systems comprising such, and polymerization processes using such.

Abstract: This invention relates to propylene polymers having multimodal molecular weight distribution and propylene polymerization processes using single site catalyst systems with supports having multimodal particle size distribution comprising one mode peaked at particle size of 3-70 ?m, and another mode peaked at particle size of 70-200 ?m, the support also having an average particle size of more than 30 ?m up to 200 ?m and a specific surface area of 400-800 m2/g.

Abstract: The present invention relates to a novel ligand compound, a transition metal compound and a catalyst composition including the transition metal compound. The novel ligand compound and the transition metal compound of the present invention may be usefully used as the catalyst of a polymerization reaction for preparing an olefin polymer having a low density relative to a CGC catalyst. In addition, a product having a low melt index (MI) and a high molecular weight may be manufactured using the olefin polymer polymerized using the catalyst composition including the transition metal compound.

Abstract: The present invention relates to salts of etheramines and polymeric acid, and in particular to salts of etheramines and polycarboxylic acid and their manufacturing process.

Abstract: The present invention provides a transition metal compound, a catalyst composition comprising the same, and a method for producing an olefin polymer using the catalyst composition, the transition metal compound being capable of exhibiting high activity in olefin polymerization reaction, and also being capable of easily controlling the physical properties of an olefin polymer. When the transition metal compound is used, it is possible to provide an olefin polymer having an excellent energy-saving effect at the time of processing or molding.

Abstract: The present invention relates to a polyolefin which exhibits a narrow molecular weight distribution, high strength, and a high stretching ratio, and a preparation method therefor. According to the present invention, it is possible to provide polyethylene with high catalyst activity, high molecular weight, and controlled molecular weight distribution by using, in polymerization of an olefin monomer, a hybrid supported metallocene catalyst in which a borate compound is used as a second cocatalyst. In addition, if the polyolefin is processed, it is possible to produce a fiber with excellent mechanical properties and an excellent stretching ratio.

Abstract: This invention relates homogeneous (solution) polymerization of propylene at higher temperatures (80° C. or more) using bisindenyl metallocene catalyst compounds having long (at least 4 carbon atoms) linear alkyl groups substituted at the 2-position and substituted or unsubstituted aryl groups at the 4-position.

Abstract: The present invention relates to tackifier compounds and methods of using the same. In various embodiments, the present invention provides a tackifier compound including independently substituted or unsubstituted fused rings A and B each independently chosen from (C5-C10)cycloalkyl and (C2-C10)heterocyclyl. Fused ring A is substituted with (R1)1-8 and fused ring B is substituted with —(OC(O)R?C(O)R2)1-8. At each occurrence R? is independently chosen from (C2-C10)alkanylene, (C2-C10)alkenylene, (C2-C10)alkynylene, C5-C20(arylene), and (C1-C20)heteroarylene, wherein R? is unsubstituted or substituted. At each occurrence R1 is independently selected from —OH, —OR3, and —OC(O)R?C(O)R2. At each occurrence R2 is independently chosen from —OH, —OR3, —NH2, —NHR3, and —NR32. At each occurrence R3 is independently chosen from (C1-C10)alkanyl, (C2-C10)alkenyl, (C2-C10)alkynyl, C5-C20(aryl), and (C1-C20)heteroaryl, wherein R3 is unsubstituted or substituted.

Abstract: The present application relates to a propylene ethylene random copolymer exhibiting two melting temperatures (Tm) which differ from each other.

Abstract: A copolymer of ethylene and a conjugated diene is provided, in which ethylene content in the copolymer is greater than 20 mol %, the copolymer has a glass transition temperature between ?110° C. and ?90° C., and continuous methylene sequence lengths (MSL) in the copolymer are in a range of 12-162 methylene units.

Abstract: A nitrile group-containing copolymer rubber containing ?,?-ethylenically unsaturated nitrile monomer units in 10 to 60 wt % and having a weight average radius of gyration of 10 to 100 nm in range is provided. According to the present invention, a nitrile group-containing copolymer rubber excellent in processability and able to give cross-linked rubber excellent in normal physical properties can be provided.

Abstract: The invention relates to a process for synthesizing polyaryl ether ketones with low contents of residual materials, whether they are residual monomers or solvents of the synthetic process.

Abstract: The present invention relates to non-aqueous fluoropolymer compositions useful for the preparation of polymeric materials.

Abstract: The present invention relates to a process for producing a polyurethane sealant, which comprises mixing (a) polyisocyanate, (b) polyetherpolyols, (c) aliphatic, exclusively amine initiated alkoxylation products having an OH-number of 400 to 1000 mg KOH/g and a functionality of 4, (d) blowing agents and optionally (e) chain extenders and/or crosslinking agents, (f) catalysts and (g) auxiliaries and/or additives to give a reaction mixture and reacting the reaction mixture to give the polyurethane sealant. The present invention further relates to a cast in place polyurethane sealant, obtained according to a process according to the present invention.

Abstract: A polyurethane composite element has one or more gaps containing a polyurethane foam. The polyurethane foam has a density of 16-40 kg/m3 and a closed cell proportion of 50-90% determined according to ASTM D6226-2010 Standard Test Method. The polyurethane foam is formed by applying a polyurethane composition into the gaps in situ. A process for producing a polyurethane composite element is also described.

Abstract: A resin composition, an insulating matrix comprising the same and a circuit board using the same. The resin composition of the present invention comprises: a cross-linked polymer formed by a diamine unit containing an imide group, which is represented by the following formula (1), and an isocyanate unit represented by the following formula (2): wherein, R1, R2, A, X and a are defined in the specification.

Abstract: Provided is an epoxy resin composition for giving a carbon fiber-reinforced composite material that simultaneously achieves tensile strength and compressive strength. An epoxy resin composition containing at least the following constituent elements [A]-[D] wherein the epoxy resin composition contains 5-50 mass % of constituent element [A] and 20-95 mass % of constituent element [B] relative to 100 mass % of total epoxy resin weight. [A]: at least one epoxy resin selected from 1,2-bis(glycidyloxy)benzene, 1,3-bis(glycidyloxy)benzene, 1,4-bis(glycidyloxy)benzene, derivatives of these, and epoxy resins having a structure represented by general formula [1] (in general formula [1], at least one of R1-R5 and at least one of R6-R10 is a glycidyl ether group, and the other R1-R10 represent any of a hydrogen atom, halogen atom, or aliphatic hydrocarbon group having four or fewer carbon atoms.

Abstract: Latent epoxy resin formulations are suitable for liquid impregnation processes for production of fiber composite materials.

Abstract: The present invention is a hydrogenated cycloolefin ring-opening polymer comprising a repeating unit derived from tetracyclododecene, and a repeating unit derived from an additional norbornene-based monomer, the hydrogenated cycloolefin ring-opening polymer having a racemo diad ratio of 65% or more with respect to the repeating unit derived from tetracyclododecene, the hydrogenated cycloolefin ring-opening polymer having a weight average molecular weight (Mw) of 10,000 to 40,000, and a resin formed article obtained by forming the hydrogenated cycloolefin ring-opening polymer having a glass transition temperature of 140 to 165° C., a melt flow rate of 8 g/10 min or more as measured at a temperature of 280° C. under a load of 21.18 N, and a flexural strength of 60 MPa or more as measured by a flexural test at a test speed of 2 mm/min, and a resin formed article, and an optical member.